Development of a Predictive Tool for Personalized Treatment of Metastatic Non-Small Lung Cancer

10 September 2023
Development of a Predictive Tool for Personalized Treatment of Metastatic Non-Small Lung Cancer

Lung cancer is the second most common cancer type worldwide, exceeded only by breast cancer. With more than 1,700,000 deaths annually, lung cancer currently accounts for the most cancer deaths worldwide. The most common type of lung cancer among the global adult population is non-small cell lung cancer (NSCLC), which accounts for approximately three quarters of all lung cancer cases. Unfortunately, there are currently limited treatment options available for metastatic NSCLC (mNSCLC), which makes personalized treatment plans crucial for improving patient outcomes.

The project shown in this case study aimed to create an analysis tool which could be valuable in helping doctors predict outcomes of mNSCLC patient treatment based on individual factors, disease characteristics and existing therapy regimens. 

Download the case study below to learn more about this project of Therapyte.

Predictive Tool for Personalized Treatment of mNSCLC
Download
Therapyte — Metastatic Non-Small Cell Lung Cancer: Case Study